Universal Beteiligungs und Servicegesellschaft mbH Buys 21,165 Shares of Edwards Lifesciences Corporation $EW

Universal Beteiligungs und Servicegesellschaft mbH raised its stake in Edwards Lifesciences Corporation (NYSE:EW) by 1.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,569,237 shares of the medical research company’s stock after acquiring an additional 21,165 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Edwards Lifesciences were worth $134,141,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in Edwards Lifesciences by 7.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after purchasing an additional 9,069 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after purchasing an additional 10,078 shares in the last quarter. Atlantic Union Bankshares Corp boosted its stake in Edwards Lifesciences by 2,240.9% in the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after purchasing an additional 11,384 shares in the last quarter. Washington Trust Advisors Inc. boosted its stake in Edwards Lifesciences by 15.6% in the third quarter. Washington Trust Advisors Inc. now owns 130,587 shares of the medical research company’s stock worth $10,156,000 after purchasing an additional 17,625 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Edwards Lifesciences by 8.1% in the third quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the sale, the vice president owned 33,934 shares in the company, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 22,680 shares of the company’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at $1,704,682.56. This represents a 51.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 86,058 shares of company stock worth $7,118,636. 0.31% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on EW shares. BTIG Research reissued a “buy” rating and issued a $103.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Barclays reissued an “overweight” rating and issued a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Truist Financial set a $89.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a research note on Tuesday, January 20th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.74.

Edwards Lifesciences Trading Down 2.0%

NYSE EW opened at $79.79 on Wednesday. The stock has a 50-day simple moving average of $81.43 and a 200 day simple moving average of $82.18. The company has a market capitalization of $46.00 billion, a PE ratio of 43.60, a P/E/G ratio of 2.12 and a beta of 0.95. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $69.21 and a 12 month high of $87.89.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion during the quarter, compared to the consensus estimate of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.96 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.